抽象的な
Stroke prevention with novel oral anticoagulants in patients with nonvalvular atrial fibrillation
Dylan Rajaratnam, Rohan Rajaratnam
Due to the ease of treatment with Novel Oral Anticoagulants (NOACs) when compared to Vitamin K antagonist, Warfarin, this is increasingly becoming the first line anticoagulant in most circumstances. Here we review the major trials of the more readily available NOACs in stroke prevention in the setting of non-valvular atrial fibrillation.
免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。